is alchemia a potential imclone?

I don't know, but it's worth considering.

ImClone really only had one product to market (Erbitux) when it was bought by Eli Lilly for $6.5 billion back in 2008. Around that time, Erbitux sales were a bit over $1 billion pa and the marketing rights were only US. They had a few drugs in the pipeline, and Erbitux was being looked at for other indications. One of those drugs, ramucirumab, has just been FDA approved for gastric cancer.

Alchemia is positioned with a late-stage development drug that may well displace irinotecan that had sales for Pfizer of $1 billion pa. It also has others in the pipeline ready to roll out using the same technology.

ImClone = $6.5 billion
Alchemia = $0.15 billion.